A real-world study of Afatinib plus ramucirumab in treatment-naive, EGFR-mutated, non-small cell lung cancer

Article Oncology

Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation

Hiroaki Akamatsu et al.

Summary: The study results indicate that the combination of osimertinib plus ramucirumab is safe and effective in patients with EGFR-mutated lung adenocarcinoma, with potential for further investigation into its efficacy.

ANTICANCER RESEARCH (2021)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Review Oncology

EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations

Edward S. Kim et al.

Summary: Data comparing outcomes of different EGFR tyrosine kinase inhibitors in Asian patients with EGFR mutation-positive non-small-cell lung cancer are limited. While first- and second-generation TKIs show similar outcomes in Asian and non-Asian populations, the third-generation TKI osimertinib does not confer the same overall survival benefit in Asians, particularly in well-resourced countries like Japan. Head-to-head comparisons of second- and third-generation EGFR TKIs should be considered in Asia.

FUTURE ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A real-world study in advanced non-small cell lung cancer with de novo brain metastasis

Lei Lei et al.

Summary: Brain metastases are a major cause of reduced life expectancy for lung cancer patients. The prognostic importance of EGFR mutation subtypes and the survival benefits of EGFR-tyrosine kinase inhibitors remain unclear for NSCLC patients with de novo brain metastases. This study examined a nationwide real-world population to assess the impact of genomic and therapeutic factors on overall survival (OS). Among patients with EGFR mutations, those treated with icotinib showed improved OS compared to those treated with gefitinib and erlotinib. Additionally, factors such as histology, number of brain metastases, and extracranial metastases status were identified as independent negative prognostic factors for both iPFS and OS in all patients.

JOURNAL OF CANCER (2021)

添加到收藏夹

Article Oncology